Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

China approves COVID-19 vaccine from Sinopharm

By Brian Buntz | December 31, 2020

SinopharmChinese health authorities have authorized a SARS-CoV-2 vaccine from state-owned Sinopharm (OTCMKTS: SHTDY). The vaccine has an efficacy of 79% based on an interim analysis of a Phase 3 study. 

China plans to distribute the BBIBP-CorV vaccine to citizens at no cost and distribute it to other countries that test Chinese vaccine candidates. 

The country has already begun mass vaccination, granting emergency use of the vaccine to essential workers, students and diplomats. 

Sinopharm chairman Liu Zingzhen stated on Nov. 20 that more than 66,000 Chinese recipients of the vaccine had traveled abroad without contracting COVID-19. 

The 79% efficacy rate, however, was lower than the 86% efficacy researchers in the United Arab Emirates reported on Dec. 9 in Phase 3 interim analysis for the Sinopharm vaccine. 

Sinopharm and its domestic competitor Sinovac employ inactivated coronaviruses in their vaccines. The downside to that approach is biosecurity, as it requires working with large amounts of coronavirus samples. 

To create the vaccine, Beijing Institute scientists procured three COVID-19 strains from hospitalized patients, selecting a variant that grew in monkey kidney cells within a bioreactor. They then inactivated the virus with the chemical beta-propiolactone

While the approach has been commonly used for decades, other prominent vaccine developers such as Moderna (NSDQ:MRNA) and Pfizer (NYSE:PFE) and partner BioNTech have opted to use mRNA technology. In contrast, the Oxford-AstraZeneca (LON:AZN) vaccine uses a chimpanzee adenovirus-vector. 


Filed Under: clinical trials, Drug Discovery, Infectious Disease
Tagged With: AstraZeneca plc, BioNTech, clinical trials, coronavirus, covid-19, COVID-19 vaccine, COVID-19 vaccine trial, Moderna, Sinopharm
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at [email protected].

Related Articles Read More >

If Trump gets Europe to pay more for drugs, more new medicines could follow — eventually
Antibody - visual concept of immune System - 3D illustration
Fresenius picks the biosimilars, WuXi Biologics builds them in a deal covering up to 37 candidates
Physician in a white coat reviewing information on a tablet with a patient in an exam room.
What real-world data shows about current cancer care
Roche Towers, Basel, Switzerland
Roche picks cancer targets, Hansoh builds the ADCs in deal with $400 million upfront
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE